Paper Details

  1. Home
  2. Paper Details

HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.

Author: BigelowGeorge E, BroonerRobert K, JohnsonRolley E, LottDavid C, StrainEric C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

A clinical trial comparing three opioid substitution medications (LAAM, BUP, and METH) for reducing HIV risk behaviors in opioid-dependent patients found that all three medications effectively decreased injecting and equipment sharing behaviors. However, only METH consistently reduced sexual risk behaviors. This suggests that while all three medications can be effective in reducing HIV risk, METH may have specific effects on sexual behaviors.
Paper Details　
Original Abstract of the Article :
The efficacies of three opioid substitution medications for reducing HIV risk behaviors in opioid-dependent patients were assessed in a randomized double-blind clinical trial comparing levomethadyl acetate [corrected] (LAAM), buprenorphine (BUP), and methadone (METH). Individually optimized flexible...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jsat.2006.04.005

データ提供：米国国立医学図書館（NLM）

Navigating HIV Risk During Opioid Dependence Treatment

This study explores the complex landscape of HIV risk behaviors in individuals receiving pharmacologic treatment for opioid dependence. The researchers compared the effectiveness of three opioid substitution medications – levomethadyl acetate (LAAM), buprenorphine (BUP), and methadone (METH) – in reducing HIV risk behaviors.

This research is important for its focus on public health implications of opioid dependence treatment and the potential for reducing HIV transmission.

Effective Opioid Substitution Medications in Reducing HIV Risk Behaviors

The study found that all three medications were effective in reducing most injecting and equipment sharing risk behaviors. However, only methadone consistently reduced sexual risk behaviors, potentially due to its side effects. This study provides valuable insights for clinicians and public health officials in selecting and managing opioid substitution medications.

Managing HIV Risk in Opioid Dependence Treatment: Dr. Camel's Perspective

Treating opioid dependence is a complex journey, like navigating a vast desert. This research provides valuable information for ensuring the safety and well-being of individuals undergoing treatment, while also minimizing the risk of HIV transmission.

Dr.Camel's Conclusion

This study, like a well-charted oasis in the desert of opioid dependence treatment, offers valuable insights into reducing HIV risk behaviors. While all three medications demonstrated effectiveness, the study highlights the importance of individualized care and considering the potential side effects of each medication.

Date :
  1. Date Completed 2007-01-03
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

16919747

DOI: Digital Object Identifier

10.1016/j.jsat.2006.04.005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.